Loading organizations...
§ Private Profile · New Haven, CT, USA
Develops nanoparticle-based drug delivery technology for improved drug efficacy and safety, focused on cancer therapeutics.
Key people at Carigent Therapeutics.
Based in New Haven, Connecticut, Carigent Therapeutics is a biotechnology company that develops nanoparticle-based drug delivery technology designed to improve the efficacy and safety of therapeutic and diagnostic agents. The company's proprietary platform attaches biological targeting agents to biodegradable polymer nanoparticles at high densities, enabling controlled release directly into specific diseased tissues and cells. While initial internal product development focuses primarily on oncology and cancer therapeutics, the firm also provides technology access through licensing collaborations with global pharmaceutical and biotechnology companies. Operating with foundational technology exclusively licensed from Yale University, the organization secured $2 million in Series A financing in December 2007 to advance its clinical pipeline under the scientific direction of Peter Fong. Carigent Therapeutics was established and founded in 2007 by biomedical engineering researchers and scientific co-founders W. Mark Saltzman and Tarek Fahmy.
Carigent Therapeutics is a biotechnology company headquartered in New Haven, CT, focused on developing next-generation therapeutic agents using a proprietary drug delivery platform.[1][2][5] The platform enables controlled release of targeted drugs and diagnostics through engineered nanoparticles, addressing key challenges in drug delivery such as precise dosing, targeted administration, and improved efficacy.[2][6] It serves the pharmaceutical and biotech sectors by solving problems like inconsistent drug release, off-target effects, and suboptimal bioavailability, with early growth marked by a completed Series A financing round to advance its nanotechnology pipeline.[6]
Founded in 2007, Carigent Therapeutics emerged as a biotech innovator in the United States, leveraging nanotechnology to pioneer advanced drug delivery solutions.[3] Key details on founders include mention of a co-founder highlighting the technology's potential in a 2007-era announcement tied to its Series A completion, emphasizing four core promises: controlled drug release, targeting, and enhanced delivery.[6] Early traction came from securing Series A funding, which propelled development of its nanoparticle-based platform for therapeutics and diagnostics, setting the stage for its focus on robust, next-gen agents.[1][6]
Carigent rides the wave of nanotechnology in drug delivery, a trend accelerating due to demands for precision medicine amid rising chronic disease prevalence and the need for targeted therapies.[1][2] Timing aligns with post-2007 biotech funding booms and advances in nanomaterials, fueled by market forces like aging populations and personalized medicine pushes. By influencing ecosystem partners through its platform, Carigent contributes to scalable solutions for complex diseases, amplifying biotech's shift toward smarter, patient-centric innovations.[6]
Carigent's nanoparticle platform positions it for expansion into advanced therapeutics, potentially partnering with big pharma for clinical trials or licensing deals. Trends like AI-driven drug design and combo therapies will shape its path, evolving its influence from early-stage innovator to key player in targeted delivery ecosystems. As biotech matures, expect Carigent to deliver on its core promises, transforming drug challenges into breakthroughs that echo its founding vision.[6]
Key people at Carigent Therapeutics.
